A Phase 1 Study to Assess the Safety,Tolerability, and Pharmacokinetics of GS-6615 in Healthy Subjects
A Phase 1, Single-Blind, Randomized, Placebo-Controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of GS-6615 in Healthy Subjects
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
Wisconsin
-
Madison, Wisconsin, Forenede Stater, 53704
- Investigational Site
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Weight of at least 50 kg with body mass index (BMI) between 18 and 30 kg/m2
- Female subjects must be of non-childbearing potential as defined per the protocol
- Male subjects with female partners of childbearing potential must be using protocol acceptable methods of contraception
- Willing and able to comply with the requirements of the protocol and directions
- Willing to avoid consumption of grapefruit, grapefruit juice and Seville oranges
- Willing to avoid consumption of nicotine (including nicotine gum) and alcoholic beverages
Exclusion Criteria:
- Ongoing or history of any medical or surgical condition that, in the judgment of the Investigator, might jeopardize the subject's safety or interfere with the study objectives
- History of meningitis or encephalitis, seizures, migraines, tremors, myoclonic jerks, sleep disorder, anxiety, syncope, head injuries or a family history of seizures
- Any abnormal ECG findings, abnormal laboratory value, or physical examination findings at Screening judged to be clinically significant
- Any abnormal neurological examination findings at Screening that is judged as clinically significant
- Hemoglobin < 12 g/dL
- Serology test positive for HIV, or hepatitis B or C
- Positive urine drug test (including cotinine or ethanol)
- Use of systemic prescription medications or over the counter (OTC) medication, including multivitamins, and dietary and herbal supplement
- Use of any experimental or investigational drug or device within 30 days
- Female subjects who are of childbearing potential, pregnant or lactating
- Donation or loss of blood within 8 weeks and/or donation of plasma within 7 days
- History of drug or alcohol abuse
- Psychosocial or addictive disorders
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Faktoriel opgave
- Maskning: Enkelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Cohort 1
Randomized to 6 mg once daily (Days 1-7) followed by 3 mg once daily (Days 8-21) of GS-6615 or matching placebo
|
GS-6615 tablet(s) administered orally once daily
Placebo tablet(s) to match GS-6615 administered orally once daily
|
|
Eksperimentel: Cohort 2
Randomized to 12 mg once daily (Days 1-7) followed by 6 mg once daily (Days 8-21) of GS-6615 or matching placebo
|
GS-6615 tablet(s) administered orally once daily
Placebo tablet(s) to match GS-6615 administered orally once daily
|
|
Eksperimentel: Cohort 3
Randomized to 20 mg once daily (Days 1-7) followed by 9 mg once daily (Days 8-21) of GS-6615 or matching placebo
|
GS-6615 tablet(s) administered orally once daily
Placebo tablet(s) to match GS-6615 administered orally once daily
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Safety and tolerability of GS-6615
Tidsramme: Up to 65 days
|
The primary outcome measure is the safety and tolerability of GS-6615 including neurological findings, adverse events, clinical laboratory tests, vital signs and ECG data (PR, RR, QRS, QT, and QTc [Fridericia] interval).
|
Up to 65 days
|
|
Pharmacokinetic (PK) profile of GS-6615
Tidsramme: Up to 65 days
|
The primary outcome measure is the PK profile of GS-6615 which will be measured with Cmax, Tmax, AUCtau, AUC0-∞, T1/2, CL/F, VSS/F, and R.
|
Up to 65 days
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- GS-US-279-0102
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .